vs
Protalix BioTherapeutics, Inc.（PLX）与VerifyMe, Inc.（VRME）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是VerifyMe, Inc.的1.8倍（$9.1M vs $5.0M），Protalix BioTherapeutics, Inc.净利率更高（-60.3% vs -66.7%，领先6.3%），VerifyMe, Inc.同比增速更快（-7.4% vs -49.9%），过去两年VerifyMe, Inc.的营收复合增速更高（-5.2% vs -6.7%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
VerifyMe, Inc.是一家专注于身份核验、防伪溯源及品牌保护服务的科技企业，为消费品、制药、零售等行业客户提供安全认证工具、全链路溯源系统与用户互动解决方案，业务覆盖北美及多个海外市场。
PLX vs VRME — 直观对比
营收规模更大
PLX
是对方的1.8倍
$5.0M
营收增速更快
VRME
高出42.5%
-49.9%
净利率更高
PLX
高出6.3%
-66.7%
两年增速更快
VRME
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $5.0M |
| 净利润 | $-5.5M | $-3.4M |
| 毛利率 | 49.4% | 41.2% |
| 营业利润率 | -51.1% | -68.2% |
| 净利率 | -60.3% | -66.7% |
| 营收同比 | -49.9% | -7.4% |
| 净利润同比 | -184.8% | -38.4% |
| 每股收益（稀释后） | $-0.06 | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXVRME
| Q4 25 | $9.1M | — | ||
| Q3 25 | $17.9M | $5.0M | ||
| Q2 25 | $15.7M | $4.5M | ||
| Q1 25 | $10.1M | $4.5M | ||
| Q4 24 | $18.2M | — | ||
| Q3 24 | $18.0M | $5.4M | ||
| Q2 24 | $13.5M | $5.4M | ||
| Q1 24 | — | $5.8M |
净利润PLXVRME
| Q4 25 | $-5.5M | — | ||
| Q3 25 | $2.4M | $-3.4M | ||
| Q2 25 | $164.0K | $-291.0K | ||
| Q1 25 | $-3.6M | $-571.0K | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $3.2M | $-2.4M | ||
| Q2 24 | $-2.2M | $-346.0K | ||
| Q1 24 | — | $-553.0K |
毛利率PLXVRME
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | 41.2% | ||
| Q2 25 | 62.5% | 35.2% | ||
| Q1 25 | 19.1% | 33.4% | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | 34.9% | ||
| Q2 24 | 29.8% | 39.1% | ||
| Q1 24 | — | 39.2% |
营业利润率PLXVRME
| Q4 25 | -51.1% | — | ||
| Q3 25 | 11.9% | -68.2% | ||
| Q2 25 | 7.5% | -7.1% | ||
| Q1 25 | -41.0% | -13.3% | ||
| Q4 24 | 39.6% | — | ||
| Q3 24 | 22.2% | -52.8% | ||
| Q2 24 | -18.0% | -10.0% | ||
| Q1 24 | — | -11.2% |
净利率PLXVRME
| Q4 25 | -60.3% | — | ||
| Q3 25 | 13.2% | -66.7% | ||
| Q2 25 | 1.0% | -6.4% | ||
| Q1 25 | -35.8% | -12.8% | ||
| Q4 24 | 35.6% | — | ||
| Q3 24 | 18.0% | -44.6% | ||
| Q2 24 | -16.4% | -6.5% | ||
| Q1 24 | — | -9.6% |
每股收益（稀释后）PLXVRME
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $0.03 | $-0.26 | ||
| Q2 25 | $0.00 | $-0.02 | ||
| Q1 25 | $-0.05 | $-0.05 | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $0.03 | $-0.23 | ||
| Q2 24 | $-0.03 | $-0.03 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $11.1M |
| 总资产 | $82.3M | $13.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLXVRME
| Q4 25 | $14.7M | — | ||
| Q3 25 | $13.6M | — | ||
| Q2 25 | $17.9M | — | ||
| Q1 25 | $19.5M | — | ||
| Q4 24 | $19.8M | — | ||
| Q3 24 | $27.4M | $2.6M | ||
| Q2 24 | $23.4M | $2.9M | ||
| Q1 24 | — | $2.8M |
总债务PLXVRME
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $500.0K | ||
| Q2 24 | — | $600.0K | ||
| Q1 24 | — | $800.0K |
股东权益PLXVRME
| Q4 25 | $48.2M | — | ||
| Q3 25 | $52.9M | $11.1M | ||
| Q2 25 | $49.9M | $14.4M | ||
| Q1 25 | $45.2M | $14.6M | ||
| Q4 24 | $43.2M | — | ||
| Q3 24 | $32.4M | $10.3M | ||
| Q2 24 | $28.6M | $12.3M | ||
| Q1 24 | — | $12.4M |
总资产PLXVRME
| Q4 25 | $82.3M | — | ||
| Q3 25 | $82.3M | $13.3M | ||
| Q2 25 | $78.5M | $17.2M | ||
| Q1 25 | $73.9M | $17.1M | ||
| Q4 24 | $73.4M | — | ||
| Q3 24 | $61.6M | $14.8M | ||
| Q2 24 | $91.5M | $17.5M | ||
| Q1 24 | — | $17.9M |
负债/权益比PLXVRME
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.05× | ||
| Q2 24 | — | 0.05× | ||
| Q1 24 | — | 0.06× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $243.0K |
| 自由现金流经营现金流 - 资本支出 | $1.6M | — |
| 自由现金流率自由现金流/营收 | 17.8% | — |
| 资本支出强度资本支出/营收 | 4.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-13.6M | — |
8季度趋势，按日历期对齐
经营现金流PLXVRME
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-3.7M | $243.0K | ||
| Q2 25 | $-5.2M | $710.0K | ||
| Q1 25 | $-5.1M | $-404.0K | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $4.1M | $-10.0K | ||
| Q2 24 | $-3.6M | $372.0K | ||
| Q1 24 | — | $-60.0K |
自由现金流PLXVRME
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-4.2M | — | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | $-12.0K | ||
| Q2 24 | $-3.8M | $369.0K | ||
| Q1 24 | — | $-62.0K |
自由现金流率PLXVRME
| Q4 25 | 17.8% | — | ||
| Q3 25 | -23.7% | — | ||
| Q2 25 | -36.2% | — | ||
| Q1 25 | -53.0% | — | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | -0.2% | ||
| Q2 24 | -28.1% | 6.9% | ||
| Q1 24 | — | -1.1% |
资本支出强度PLXVRME
| Q4 25 | 4.4% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 1.3% | 0.1% | ||
| Q1 24 | — | 0.0% |
现金转化率PLXVRME
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
VRME
| Proactive Services | $4.2M | 83% |
| Other | $869.0K | 17% |
